Today: 20 May 2026
Browse Category

NASDAQ:RVPH 24 October 2025 - 9 March 2026

Reviva Pharmaceuticals Holdings (RVPH) Starts 1-for-20 Reverse Split as Nasdaq Deadline Nears

Reviva Pharmaceuticals Holdings (RVPH) Starts 1-for-20 Reverse Split as Nasdaq Deadline Nears

Reviva Pharmaceuticals enacted a 1-for-20 reverse stock split early Monday to boost its share price and avoid a Nasdaq delisting. The company faces a March 27 deadline to meet the $1 minimum bid rule. Reviva is also seeking funding for a new Phase 3 trial of its schizophrenia drug after the FDA requested more data. Analyst Jason Kolbert downgraded the stock, citing unchanged fundamentals.
9 March 2026
·
Reviva Pharmaceuticals (RVPH) Stock Plunges After FDA Calls for Second Phase 3 Trial: News, Forecasts, and Analyst Takeaways on Dec. 24, 2025

Reviva Pharmaceuticals (RVPH) Stock Plunges After FDA Calls for Second Phase 3 Trial: News, Forecasts, and Analyst Takeaways on Dec. 24, 2025

Reviva Pharmaceuticals shares fell to $0.32 on December 24, 2025, after the FDA recommended a second Phase 3 trial for its schizophrenia drug brilaroxazine before a New Drug Application. The company said the new trial, RECOVER-2, could cost $60 million and delay potential approval to late 2028. Reviva plans to start the trial in the first half of 2026, pending financing.
24 December 2025
···
Reviva Pharmaceuticals (RVPH) Stock Today: Price, News, Forecast & Schizophrenia NDA Setup – 10 December 2025

Reviva Pharmaceuticals (RVPH) Stock Today: Price, News, Forecast & Schizophrenia NDA Setup – 10 December 2025

Reviva Pharmaceuticals (RVPH) traded around $0.69 per share mid-session December 10, up 10% on the day but still down 72% over the past year. Market cap stood near $78–80 million. On December 9, call options volume spiked 458% above average as traders speculated on upcoming catalysts. The company’s lead drug, brilaroxazine, recently completed Phase 3 trials in schizophrenia.
10 December 2025
··
Reviva Pharma Rockets 28% on Schizophrenia Trial Win – Analysts Eye 1000% Upside

Reviva Pharma Rockets 28% on Schizophrenia Trial Win – Analysts Eye 1000% Upside

RVPH shares closed at $0.57 on Oct 24 after a volatile month, swinging between $0.26 and $0.84. The stock surged 28% on Oct 23 following recent Phase 3 trial results for brilaroxazine and news of an upcoming FDA meeting. Reviva raised about $19 million this year to fund its CNS pipeline. Analyst targets average $6.25, implying a potential 1,000% upside.
24 October 2025
···

Stock Market Today

  • LVMH Share Price Down 28% YTD; Fairly Valued by Discounted Cash Flow Model
    May 20, 2026, 4:06 PM EDT. LVMH Moët Hennessy - Louis Vuitton shares have declined 28.2% in 2024, closing at €460.85, down 3.6% last week and 4.3% last month. The luxury sector's current sentiment reflects cautious premium consumer spending. A Discounted Cash Flow (DCF) analysis, projecting the company's future cash flows discounted to present value, estimates LVMH's intrinsic share value at €471.58, suggesting the stock is about 2.3% undervalued. Analysts see only modest upside potential given the tight margin between price and estimated intrinsic value. Over the past year, LVMH has returned -6.9%, aligning with broader luxury industry trends. Investors should monitor value metrics amid market uncertainties and sector reassessments.

Latest articles

Dow Jones Today: Why the Index Jumped Back Above 50,000 After the Bell

Dow Jones Today: Why the Index Jumped Back Above 50,000 After the Bell

20 May 2026
The Dow Jones Industrial Average closed above 50,000 on Wednesday, rising 1.3% to 50,005.30 after three days of declines. Tech stocks led gains, with Nvidia shares climbing ahead of its earnings report and the Philadelphia Semiconductor Index up 3.9%. Lower Treasury yields and oil prices supported the rebound. Federal Reserve minutes signaled continued concern over inflation and possible further rate hikes.
Dow Rises After Nvidia Rally Ends Three-Day Wall Street Slide

Dow Rises After Nvidia Rally Ends Three-Day Wall Street Slide

20 May 2026
The Dow rose 581.66 points to 49,945.54 as Wall Street snapped a three-day losing streak, driven by gains in chip stocks ahead of Nvidia’s earnings and relief from falling oil prices and lower Treasury yields. The Philadelphia SE Semiconductor Index jumped 3.9%, with Nvidia up 1.8%, AMD up 7.3%, and Intel up 6.7%. U.S. crude dropped $5.89 to $98.26 a barrel. Fed minutes showed officials remain cautious on rate cuts.
Bradesco Shares Up, Big Test Ahead for Brazil’s Bank Rally

Bradesco Shares Up, Big Test Ahead for Brazil’s Bank Rally

20 May 2026
Banco Bradesco’s preferred shares rose 3.28% to R$17.96 on Wednesday, outperforming the Ibovespa’s 2.12% gain as Brazilian bank stocks rebounded. Bradesco reported first-quarter recurring net income of R$6.8 billion, up 16.1% year-on-year, but loan-loss provisions increased 26.5% to R$9.7 billion. The Selic rate remains at 14.5% after recent cuts, with inflation expectations rising.
Go toTop